三阴性乳腺癌（TNBC）具有高度异质性，侵袭性强，没有特定的分子治疗靶点，因而临床预后较差。肿瘤浸润淋巴细胞（TILs）在肿瘤微环境中扮演重要角色，可以参与抗肿瘤免疫反应，被认为是TNBC的预后指标。高水平的TILs与TNBC患者病理完全反应增加有关。目前，有关自体TILs给药或免疫检查点抑制剂的研究受到广泛关注，可以为TNBC提供免疫治疗靶点，并改善TNBC的临床预后。

[1] FAN L,STRASSER-WEIPPL K,LI J J,et al.Breast cancer in China[J].Lancet Oncol,2014,15(7):e279-e289.
[2] 陈梅林,苏贞绍,颜永清,等.维生素D联合Ki67在三阴性乳腺癌预后中的价值[J].现代医学,2020,48(8):971-977.
[3] LEE H J,PARK I A,SONG I H,et al.Tertiary lymphoid structures:prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer[J].J Clin Pathol,2016,69(5):422-430.
[4] WURFEL F,ERBER R,HUEBNER H,et al.TILGen:A program to investigate immune targets in breast cancer patients-first results on the influence of tumor-infiltrating lymphocytes[J].Breast Care (Basel),2018,13(1):8-14.
[5] PRUNERI G,VINGIANI A,BAGNARDI V,et al.Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer[J].Ann Oncol,2016,27(2):249-256.
[6] HERRERO-VICENT C,GUERRERO A,GAVILA J,et al.Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy[J].Ecancermedicalscience,2017,11:759.
[7] INGOLD HEPPNER B,UNTCH M,DENKERT C,et al.Tumor-infiltrating lymphocytes:A predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer[J].Clin Cancer Res,2016,22(23):5747-5754.
[8] MAO Y,QU Q,CHEN X,et al.The prognostic value of tumor-infiltrating lymphocytes in breast cancer:a systematic review and meta-analysis[J].PloS One,2016,11(4):e0152500.
[9] GAO G,WANG Z,QU X,et al.Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer:a systematic review and meta-analysis[J].BMC Cancer,2020,20(1):179.
[10] LOI S,DRUBAY D,ADAMS S,et al.Tumor-infiltrating lymphocytes and prognosis:A pooled individual patient analysis of early-stage triple-negative breast cancers[J].J Clin Oncol,2019,37(7):559-569.
[11] LEON-FERRE R A,POLLEY M Y,LIU H,et al.Impact of histopathology,tumor-infiltrating lymphocytes,and adjuvant chemotherapy on prognosis of triple-negative breast cancer[J].Breast Cancer Res Treat,2018,167(1):89-99.
[12] PARK J H,LEE H J,LEE S B,et al.Intrinsic prognostic impact of tumor-infiltrating lymphocytes in systemically untreated patients with early-stage triple-negative breast cancer[J].Anticancer Res,2019,39(6):3111-3119.
[13] 林嘉燕,张建国.乳腺癌新辅助化疗疗效的评估方法及其进展[J].东南大学学报(医学版),2019,38(4):727-731.
[14] DENKERT C,VON MINCKWITZ G,DARB-ESFAHANI S,et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer:a pooled analysis of 3771 patients treated with neoadjuvant therapy[J].Lancet Oncol,2018,19(1):40-50.
[15] ASANO Y,KASHIWAGI S,GOTO W,et al.Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer[J].Br J Surg,2016,103(7):845-854.
[16] LUEN S J,SALGADO R,DIECI M V,et al.Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy[J].Ann Oncol,2019,30(2):236-242.
[17] BAI Y G,GAO G X,ZHANG H,et al.Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy[J].Chin Med J,2020,133(5):552-560.
[18] PINARD C,DEBLED M,BEN REJEB H,et al.Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy[J].Breast Cancer Res Treat,2020,179(1):11-23.
[19] HAMY A S,BONSANG-KITZIS H,DE CROZE D,et al.Interaction between molecular subtypes and stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy[J].Clin Cancer Res,2019,25(22):6731-6741.
[20] LEE H,LEE M,SEO J H,et al.Changes in tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and clinical significance in triple negative breast cancer[J].Anticancer Res,2020,40(4):1883-1890.
[21] GUO W,LU X,LIU Q,et al.Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients:an updated meta-analysis of 17079 individuals[J].Cancer Med,2019,8(9):4135-4148.
[22] AFGHAHI A,PURINGTON N,HAN S S,et al.Higher absolute lymphocyte counts predict lower mortality from early-stage triple-negative breast cancer[J].Clin Cancer Res,2018,24(12):2851-2858.
[23] LEE J,KIM D M,LEE A.Prognostic role and clinical association of tumor-infiltrating lymphocyte,programmed death ligand-1 expression with neutrophil-lymphocyte ratio in locally advanced triple-negative breast cancer[J].Cancer Res Treat,2019,51(2):649-663.
[24] ROMERO-CORDOBA S,MENEGHINI E,SANT M,et al.Decoding immune heterogeneity of triple negative breast cancer and its association with systemic inflammation[J].Cancers (Basel),2019,11(7) pii:E911.
[25] ASSADIPOUR Y,ZACHARAKIS N,CRYSTAL J S,et al.Characterization of an immunogenic mutation in a patient with metastatic triple-negative breast cancer[J].Clin Cancer Res,2017,23(15):4347-4353.
[26] SAVAS P,VIRASSAMY B,YE C,et al.Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis[J].Nat Med,2018,24(7):986-993.
[27] ZHU X,ZHANG Q,WANG D,et al.Expression of PD-L1 attenuates the positive impacts of high-level tumor-infiltrating lymphocytes on prognosis of triple-negative breast cancer[J].Cancer Biol Ther,2019,20(8):1105-1112.
[28] STOVGAARD E S,NIELSEN D,HOGDALL E,et al.Triple negative breast cancer-prognostic role of immune-related factors:a systematic review[J].Acta Oncol,2018,57(1):74-82.
[29] SCHMID P,ADAMS S,RUGO H S,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med,2019,380(10):987-988.